Trial intelligence / Profile preview

Lunsekimig in chronic rhinosinusitis with nasal polyps

2024-511261-11-00Phase 2Completed

Sponsor: Sanofi
Start: Aug 2024
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 6

Overview

Phase 2, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Lunsekimig arm with Placebo arm (2 arms). Primary endpoint: Change in bilateral endoscopic nasal polyp score (NPS). Started Aug 2024; status: completed.

Drugs

lunsekimig

Conditions

chronic rhinosinusitis with nasal polyps (CRSwNP)

Beyond the preview

Go deeper on 2024-511261-11-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-511261-11-00.